1558036-85-3

Usage

Molecular structure

The compound has a complex molecular structure consisting of a piperidin-3-yl acryloyl group, an amino group, a phenoxyphenyl group, and a pyrazole carboxamide group.

Stereochemistry

The compound has a specific stereochemistry at the piperidin-3-yl acryloyl group, with the (3R) configuration.

Amino group

The presence of an amino group in the molecule suggests potential reactivity and the possibility of forming salts or coordination compounds.

Phenoxyphenyl group

The phenoxyphenyl group is a common structural motif in many biologically active compounds, which may contribute to the compound's potential biological activities.

Pyrazole carboxamide group

The pyrazole carboxamide group is a heterocyclic structure that can participate in various types of chemical reactions and may contribute to the compound's biological activity.

Potential applications

Due to its unique structural features, the compound likely possesses a diverse range of biological activities. It may have potential applications in various fields, such as pharmaceuticals, biotechnology, and materials science.

Further research needed

The specific properties and potential uses of this chemical compound are not explicitly stated in the name. Further research and testing are required to fully understand its functions and potential applications.

Biological activity

The compound's complex structure suggests that it may have various biological activities, which could be explored through in vitro and in vivo studies.

Synthesis

The synthesis of 1-[(3R)-1-acryloylpiperidin-3-yl]-5-amino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide may involve multiple steps, including the formation of the piperidin-3-yl acryloyl group, the attachment of the phenoxyphenyl group, and the formation of the pyrazole carboxamide group.

Stability

The stability of the compound under different conditions (e.g., temperature, pH, light exposure) should be investigated to determine its suitability for various applications.

Upstream product

• 2215-77-2 4-Phenoxybenzoic acid 
• 1284940-16-4 benzyl 3-(2-(tert-butoxycarbonyl)hydrazinyl)piperidine-1-carboxylate 
• 1609467-42-6 3-(tert-butoxycarbonyl-hydrazono)-piperidine-1-carboxylic acid benzyl ester 
• 61995-20-8 N-(benzyloxycarbonyl)-3-piperidone 
• 814-68-6 acryloyl chloride 
• 330792-68-2 2-[hydroxy-(4-phenoxy-phenyl)-methylene]-malononitrile 
• 1623-95-6 4-phenoxybenzoyl chloride 
• 1558038-42-8 (R)-5-amino-3-(4-phenoxyphenyl)-1-piperidin-3-yl-1H-pyrazole-4-carboxylic acid amide 
• 79-10-7 acrylic acid 
• 1609467-45-9 5-amino-3-(4-phenoxyphenyl)-1-piperidin-3-yl-1H-pyrazole-4-carboxylic acid amide 
• 1609467-44-8 5-amino-3-(4-phenoxy-phenyl)-1-piperidin-3-yl-1H-pyrazole-4-carbonitrile 
• 1609467-43-7 benzyl 3-[5-amino-4-cyano-3-(4-phenoxy-phenyl)-pyrazol-1-yl]-piperidine-1-carboxylate 
• 330792-69-3 2-[(4-phenoxy-phenyl)-methoxy-methylene]-malononitrile 

Relevant academic research and scientific papers

Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning

Potent covalent inhibitors of Bruton's tyrosine kinase (BTK) based on an aminopyrazole carboxamide scaffold have been identified. Compared to acrylamide-based covalent reactive groups leading to irreversible protein adducts, cyanamide-based reversible-covalent inhibitors provided the highest combined BTK potency and EGFR selectivity. The cyanamide covalent mechanism with BTK was confirmed through enzyme kinetic, NMR, MS, and X-ray crystallographic studies. The lead cyanamide-based inhibitors demonstrated excellent kinome selectivity and rat pharmacokinetic properties.

Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor

Therapeutic combinations of an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor and a Bruton's tyrosine kinase (BTK) inhibitor are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of an IRAK4 inhibitor and a BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

Protein Kinase Inhibitors and Uses Thereof

The invention is compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby.

METHODS OF BLOCKING THE CXCR-4/SDF-1 SIGNALING PATHWAY WITH INHIBITORS OF BRUTON'S TYROSINE KINASE

In some embodiments, the present invention relates to novel small molecule inhibitors that block the CXCR4-SDF-1 signaling pathway by directly inhibiting members of the Tec family of kinases, namely Bruton's tyrosine kinase (BTK), and their use in treating diseases in which pathogenesis is mediated by the CXCR4/SDF-1 signaling pathway.

BRUTON'S TYROSINE KINASE INHIBITORS

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

INHIBITORS OF BRUTON'S TYROSINE KINASE

The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolites, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provided the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. Formula (IV)

HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS

The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.